The COVID-19 Long Haul Foundation

Treatment, Referral & Educational Support for COVID-19 Illnesses & Vaccine Injury

Late onset and persistent parosmia and dysgeusia as neurosensorial complication by the SARS virus COV 2

Patricia Sequeira Rodriguez, Rafael Santana Ortiz,at. al.Otolaryngol 2023: 2023.  doi:  10.1016/j.xocr.2023.100510, PMCID: PMC9850639,PMID: 3669145 Abstract About the neurological manifestations of COVID-19, smell impairment with some distortion or parosmia is currently one of the […]

Therapeutic potential of convalescent plasma and hyperimmune immunoglobulins against SARS-CoV-2 BQ.1, BQ.1.1, and XBB variants

Lorenza Bellusci, Hana Golding, and Surender Khurana Journal of Clinical Investigation Published 2023 – More infoView PDF  Convalescent plasma (CP) and hyperimmune intravenous immunoglobulins (IVIGs) are routinely used to treat patients with COVID-19. […]

Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19A Randomized Clinical Trial

Susanna Naggie, MD, MHS1,2; David R. Boulware, MD, MPH3; Christopher J. Lindsell, PhD4; et alThomas G. Stewart, PhD5; Alex J. Slandzicki, MD6; Stephen, C. Lim,  MD Jonathan Cohen, MD8;  David Kavtaradze, MD9,  Arch Amon, MD10, et. al for the Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group and Investigators. JAMA. 2023;329(11):888-897. doi:10.1001/jama.2023.1650 Question  Does ivermectin, […]